[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles].

Abstract

A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, was developed for the treatment of lymph node metastases in patients with breast cancer. In a mice experimental model, ACR-CH had superior therapeutic effects on lymph node metastases compared to the same dose of ACR aqueous solution. In clinical trials, patients with breast cancer received a local injection of 10 mg/person of ACR in the form of ACR-CH or ACR aqueous solution just before mastectomy. In the regional lymph nodes removed by the operation, the ACR concentration of 40.7 micrograms/g in patients given ACR-CH was higher than the 25.1 micrograms/g in patients given ACR aqueous solution, whereas in blood plasma the concentration was higher in patients given ACR aqueous solution than in those given ACR-CH.

• Authors: T Imanishi, T Sakakibara, J Yamazaki, T Ohyama, M Shirasu, H Tsujimoto, M Ohgaki, M Shimotsuma, A Hagiwara, K Sawai
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 22 Issue 11 Pg. 1635-7 (Sep 1995) ISSN: 0385-0684 [Print] Japan
• PMID: 7574780 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Delayed-Action Preparations
• Carbon
• Aclarubicin

Topics

• Aclarubicin (administration & dosage)
• Animals
• Antibiotics, Antineoplastic (administration & dosage)
• Breast Neoplasms (drug therapy, pathology, surgery)
• Carbon
• Combined Modality Therapy
• Delayed-Action Preparations
• Female
• Humans
• Leukemia P388 (drug therapy, pathology)
• Lymphatic Metastasis
• Mastectomy
• Mice